Paper Details

  1. Home
  2. Paper Details

A translational continuum of model systems for evaluating treatment strategies in Alzheimer's disease: isradipine as a candidate drug.

Author: AnekondaThimmappa S, CopenhaverPhilip F, KretzschmarDoris, MusasheDerek, QuinnJoseph F, RamakerJenna M, RobinsonKristine M, SwansonTracy L, WadsworthTeri L, WoltjerRandall L

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Overview

Isradipine, a calcium channel blocker, shows promise for treating Alzheimer's disease (AD). In four distinct model systems, isradipine reduced the neurotoxic consequences of β-amyloid accumulation without inducing side effects.
Paper Details　
Original Abstract of the Article :
A growing body of evidence supports the 'calcium hypothesis' of Alzheimer's disease (AD), which postulates that a variety of insults might disrupt the homeostatic regulation of neuronal calcium (Ca(2+)) in the brain, resulting in the progressive symptoms that typify the disease. However, despite ong...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180227/

データ提供：米国国立医学図書館（NLM）

Isradipine: A Promising Candidate Drug for Alzheimer's Disease

Alzheimer's disease, a cruel and debilitating disease, presents a significant challenge for researchers. This research explores the potential of isradipine, a calcium channel blocker, as a treatment for Alzheimer's disease. The authors investigated the effects of isradipine on various model systems, demonstrating its ability to reduce the neurotoxic effects of amyloid beta, a protein implicated in Alzheimer's disease. The findings suggest that isradipine could be a promising drug for treating Alzheimer's disease, offering a ray of hope in the fight against this devastating condition.

Isradipine Shows Promise in Reducing Amyloid Beta Toxicity

The research suggests that isradipine could be a valuable tool for reducing amyloid beta toxicity, potentially slowing down the progression of Alzheimer's disease. This finding offers a glimmer of hope for developing more effective treatments for Alzheimer's.

Targeting Calcium Imbalances in Alzheimer's Disease

Alzheimer's disease is often linked to disruptions in calcium signaling within the brain. This research emphasizes the importance of targeting calcium imbalances in the brain to develop effective treatments for Alzheimer's disease. It could lead to new approaches for treating this complex and challenging disease.

Dr. Camel's Conclusion

This research provides promising evidence for the potential of isradipine as a treatment for Alzheimer's disease. It highlights the importance of understanding the role of calcium in the development of Alzheimer's and suggests that targeting calcium imbalances could be a key strategy for developing effective treatments.
Date :
  1. Date Completed 2011-12-30
  2. Date Revised 2021-12-03
Further Info :

Pubmed ID

21596710

DOI: Digital Object Identifier

PMC3180227

Related Literature

Article Analysis
・Side Effects of isradipine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.